Market revenue in 2023 | USD 177.7 million |
Market revenue in 2030 | USD 961.9 million |
Growth rate | 27.3% (CAGR from 2023 to 2030) |
Largest segment | Media |
Fastest growing segment | Antibodies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Media, Sera, Cell Culture Supplements, Antibodies, Reagents & Buffers |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Danaher Corp, Sartorius AG, Stemcell Holdings Inc Ordinary Shares, Grifols SA Ordinary Shares - Class A, Charles River Laboratories International Inc, Actylis, ACROBiosystems, RoosterBio, PromoCell GmbH |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell therapy raw materials market will help companies and investors design strategic landscapes.
Media was the largest segment with a revenue share of 23.8% in 2023. Horizon Databook has segmented the UK cell therapy raw materials market based on media, sera, cell culture supplements, antibodies, reagents & buffers covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the UK cell therapy raw materials market , including forecasts for subscribers. This country databook contains high-level insights into UK cell therapy raw materials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account